MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.

被引：0
|
作者：
Apfel, Athena M. [1 ]
Merrill, Nathan M. [1 ]
Vandecan, Nathalie M. [1 ]
Bao, Liwei [1 ]
Cheng, Xu [1 ]
Lopez-Barcons, Lluis A. [1 ]
Day, Kathleen C. [1 ]
Palmbos, Phillip L. [1 ]
Day, Mark L. [1 ]
Udager, Aaron M. [1 ]
Soellner, Matthew B. [1 ]
Merajver, Sofia D. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1194
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
    Ching, Christina Barbara
    Hansel, Donna Elizabeth
    LABORATORY INVESTIGATION, 2010, 90 (10) : 1406 - 1414
  • [2] Therapeutic Potential of PI3K/Akt/mTOR Signalling Pathway: Effective Combination Therapy for Cancer
    Kawade, V. S.
    Satpute, P. S.
    Dhulap, S. A.
    Gurjar, S.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 80 (04) : 702 - 708
  • [3] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [4] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
    Slomovitz, Brian M.
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864
  • [5] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Babichev, Yael
    Kabaroff, Leah
    Datti, Alessandro
    Uehling, David
    Isaac, Methvin
    Al-awar, Rima
    Prakesch, Michael
    Sun, Ren X.
    Boutros, Paul C.
    Venier, Rosemarie
    Dickson, Brendan C.
    Gladdy, Rebecca A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [6] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    Mabuchi, Seiji
    Kuroda, Hiromasa
    Takahashi, Ryoko
    Sasano, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
  • [7] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Yael Babichev
    Leah Kabaroff
    Alessandro Datti
    David Uehling
    Methvin Isaac
    Rima Al-awar
    Michael Prakesch
    Ren X. Sun
    Paul C. Boutros
    Rosemarie Venier
    Brendan C. Dickson
    Rebecca A. Gladdy
    Journal of Translational Medicine, 14
  • [8] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Qingfang Li
    Zhihui Li
    Ting Luo
    Huashan Shi
    Molecular Biomedicine, 3
  • [9] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Li, Qingfang
    Li, Zhihui
    Luo, Ting
    Shi, Huashan
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
  • [10] PI3K/AKT/mTOR
    Umemura, Shigeki
    Goto, Koichi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117
12345